What does it mean for covered entities already desperate for diminishing 340B savings and revenue?
As we noted in a previous post, 340B ESP is nothing less than a brazen and (in our opinion) unlawful ploy by the drug manufacturers to evade the discounts they are legally obligated to offer eligible entities — by placing extraordinary, and unnecessary, reporting burdens on hospitals submitting claims for 340B savings and 340B pricing.
Moreover, that estimate constitutes a fraction of the time it would take most health systems’ 340B-reporting employees to read and fully comprehend the terms (assuming full comprehension is even possible for anyone without a law degree, and significant experience in drafting and interpreting legal documents).
We cannot stress this highly enough — 340B ESP is not a government-established or approved entity. It is an online portal operated by a privately owned corporation (created and run by a man with a long history of drug-industry advocacy), with no legal right to impose its restrictions on covered entities. In short, not one “requirement” imposed on 340B-eligible entities, from this point forward, is legally binding.
Why are covered entities cooperating with 340B ESP?
340B ESP was introduced in a June 2020 letter from Merck, when it issued a “request” that 340B Covered Entities begin submitting a broad range of 340B contract pharmacy claims data, as part of what it called an “integrity initiative.” The letter warned recipients who declined to cooperate that it “may take further action to address 340B program integrity, which may include seeking 340B program claims information in a manner that will be substantially more burdensome for covered entities.” In plain English, that’s not a request, it’s a threat.
Calling attention to 340B ESP’s “hidden motives”
- A 2014 report on contract pharmacies (suggesting that 340B DSH hospitals seek out contract pharmacies in affluent areas to obtain more revenue).
- A 2018 report which suggests that there is a financial incentive for 340B hospitals to use more drugs, or more expensive drugs, on Medicare Part B beneficiaries.
- A 2018 report which suggests that the 340B program is inadequately overseen by HRSA.
- A 2014 report which suggests that 340B hospitals misuse the 340B program, and harm their patients in the process.
In short, there is a very real possibility that BRG could be using 340B pricing claims data submitted to 340B ESP to undermine the very entities it purports to be “serving.”
The real reason behind 340B ESP?
Why “Commercial Payers?” And what, in truth, are “Ineligible Rebates?”
As we mentioned in our previous post, we believe that the primary driver behind the creation of the 340B ESP system is the extensive range of commercial rebates that the manufacturers themselves have voluntarily extended to PBMs — rebates which, in total, far exceed the combined discounts of the 340B program. In short, it’s a situation of their own making, and they’re placing the burden for their mistakes on 340B covered entities.
340B ESP’s unsurpassed cheek.
In its Limitations Of Liability section, 340B ESP asserts, in all caps:
THE LIMITATIONS OF LIABILITY SHALL NOT APPLY TO SECOND SIGHT’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. SECOND SIGHT’S AGGREGATE LIABILITY FOR DIRECT DAMAGES UNDER THIS AGREEMENT WILL NOT EXCEED ONE HUNDRED DOLLARS ($100).
And unsurpassed irony.
“You acknowledge and grant us the right to…report any activity that we suspect may violate any law or regulation to regulators, law enforcement officials or other persons or entities that we deem appropriate.” Again, this is coming from an organization operating wholly outside the regulations set-forth by Congress and established by HRSA.
As the advocacy group 340B Health further notes in its lengthy analysis of 340B ESP, Under any analysis, Merck’s request for contract pharmacy data on commercial claims is outside the scope of the 340B statute, suggesting that Merck’s plan is not based solely on ensuring covered entity compliance with 340B rules.
Federal law does not protect manufacturers from providing 340B discounts on Medicare Part D claims, nor does it require covered entities to help prevent a manufacturer from paying both a 340B discount and a commercial rebate that manufacturers voluntarily provide to PBMs on the same drug.
Accordingly, Merck’s request that covered entities share contract pharmacy claims data to ensure it is not paying “duplicate discounts” on Medicare Part D and commercial claims is unrelated to compliance obligations 340B covered entities have under the 340B program.
The Covered Entity Platform is subject to modification (including addition, alteration, or deletion) by Second Sight in its sole discretion.
You understand that Second Sight may at any time and from time to time modify or discontinue access to the Covered Entity Platform (or any part), with or without notice, temporarily or permanently…
Upon termination…Second Sight shall have no obligation to return to you any data stored on Second Sight’s systems.
You expressly acknowledge and agree that the Participating Pharmaceutical Manufacturers are third party beneficiaries of these Terms and have the full rights to enforce these Terms as if any one of them was a signatory hereto.
You specifically authorize our use of subcontractors and our right to delegate any of the rights or obligations hereunder.
Second Sight may revise these Terms from time to time by posting such revised Terms on this website, or otherwise notifying you in advance of making effective such revisions to the Terms. Such revised Terms shall be effective to you upon the effective date provided in the posting or other notice, unless otherwise explicitly stated by Second Sight. It is your responsibility to be aware of any such revised terms by checking and reading these Terms from time to time and your notices.
The good news about 340B ESP, for covered entities
Despite the well-founded outrage over 340B ESP, not to mention manufacturer restrictions on legitimate 340B pricing, ProxsysRx continues to generate significant savings and revenues for the health systems we serve. Savings and revenue which, for many of those health systems, literally means the difference between solvency and closure.
One of the health systems ProxsysRx serves employs three experienced and well-trained full-time professionals — who monitor their systems’ contract pharmacies’ 340B claims, and 340B claims data, on a full-time basis. And yet, during the first six weeks ProxsysRx supported their efforts, we provided matching justification for, and generated $187,000 worth of, 340B savings that they’d overlooked.
Altogether, our efforts have generated tens of millions in 340B savings and revenue for the hospitals we serve.
ProxsysRx is here to help, if you have questions.
There are so many ways to optimize your 340B drug program savings and benefits, while minimizing the likelihood of noncompliance. For more information, contact Howard Hall. C: 205.588.0946 | firstname.lastname@example.org